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ABSTRACT
The role of autologous or allogeneic blood or marrow transplantation (BMT) remains undefined in patients
with central nervous system (CNS) involvement by lymphoma. The records of all adult and pediatric non-
Hodgkin lymphoma patients receiving BMT at Johns Hopkins from 1980 to 2003 were reviewed, and 37
patients were identified who had CNS involvement that was treated into remission by the time of BMT. The
chief histologies were diffuse large B-cell lymphoma and T-cell lymphoblastic lymphoma/leukemia. Twenty-
four percent received intrathecal chemotherapy alone, and 70% received intrathecal chemotherapy and CNS
irradiation before BMT. The main preparative regimens were cyclophosphamide/total body irradiation and
busulfan/cyclophosphamide. Forty-one percent received an allogeneic transplant. Lymphoma relapsed after
BMT in 14 patients (38%), and at least 5 had documented or suspected CNS relapse. In multivariate models,
age >18 years at diagnosis, resistant systemic disease, busulfan/cyclophosphamide conditioning, and lack of
intrathecal consolidation after BMT were statistically significant predictors of inferior survival. The 5-year
actuarial event-free survival was 36%, and overall survival was 39%. After BMT, long-term survival is thus
achievable in a subset of patients with a history of treated CNS involvement by non-Hodgkin lymphoma. The
survival rates are not dissimilar to those typically seen in other high-risk lymphoma patients undergoing BMT.
These data suggest that patients with lymphomatous involvement of the CNS who achieve CNS remission
should be offered BMT if it is otherwise indicated.
© 2005 American Society for Blood and Marrow Transplantation
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iNTRODUCTION
Central nervous system (CNS) involvement by
on-Hodgkin lymphoma (NHL) has historically car-
ied a dismal prognosis. In prior series, survival has
ypically been measured in months [1-7]. Currently,
here is no consensus regarding the optimal treatment
or these patients. There are multiple potential barri-
rs to the achievement of long-term remission in pa-
ients with NHL involving the CNS, including ad-
anced systemic disease, therapeutic toxicities, and the
ifﬁculty inherent to treating lymphoma in a sanctu-
B&MTry site. Conventional doses of most chemotherapeu-
ic agents have poor penetration into the CNS [8,9].
ntraventricular or intrathecal administration of che-
otherapy can in part circumvent this problem; how-
ver, toxicities are often dose limiting, and CNS pen-
tration by chemotherapeutic agents can be uneven.
ortions of the CNS may therefore remain untreated,
eading to disease persistence and the potential for
ystemic reseeding. Cranial or spinal irradiation can
e effective in this regard, but at the potential cost of
ncreased neurotoxicity, including late effects [10].High doses of chemotherapy with or without total
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9ody irradiation (TBI) given in the setting of blood or
arrow transplantation (BMT) may both reach dis-
ase sanctuaries and eradicate systemic disease, thus
mproving overall survival [11-14]. However, available
ata do not permit conclusive recommendations on
he role of BMT in patients with CNS involvement by
ymphoma, and there has been a relatively high rate of
eurotoxicity [13]. To evaluate the role of high-dose
herapy combined with BMT in such patients, we
escribe the outcomes of 37 patients with prior lym-
homatous involvement of the CNS who underwent
MT at our institution. We report prognostic models
or event-free and overall survival and discuss treat-
ent considerations in patients with this presentation.
ATERIALS AND METHODS
tudy Population
We screened the medical records of all individuals
ho received an autologous or allogeneic BMT for
HL at the Johns Hopkins Oncology Center between
980 and 2003. Permission to perform this study was
ranted by the institutional review board. Patients
ho had leptomeningeal or intraparenchymal CNS
nvolvement by lymphoma and who had reached CNS
emission before BMT were selected for this analysis.
Patients with primary CNS lymphoma or B-lin-
age acute lymphoblastic leukemia were excluded. All
riginal diagnostic specimens were reviewed by the
athology department at Johns Hopkins. Allogeneic
MT was prioritized in patients50 years of age who
ad an HLA-identical sibling. The transplantation
as performed in accordance with institutional poli-
ies or approved protocols in effect at the time. Intra-
hecal consolidation after BMT was routinely recom-
ended for patients with prior CNS disease or for
hose with other high-risk features, such as bone mar-
ow involvement by aggressive lymphoma.
Patients with CNS disease present at initial diag-
osis, during ﬁrst-line therapy, or upon systemic or
solated CNS relapse were included. Lymphomatous
nvolvement of the CNS was diagnosed on the basis of
ytopathologic examination of the cerebrospinal ﬂuid
CSF) or tissue biopsy samples, with or without char-
cteristic radiographic and neurologic ﬁndings. In
ases of suggestive but not deﬁnitive cytopathology,
ncreased CSF protein or characteristic radiographic
igns were required. Radiographic signs were consid-
red characteristic of leptomeningeal or intraparen-
hymal disease if there was no evidence supporting
ny other reasonable or likely cause of the ﬁndings,
uch as infection, a vascular event, or therapeutic tox-
city [2]. CNS remission was deﬁned as the clearance
f lymphoma cells from the CSF with improvement or
tabilization of neurologic symptoms and radiographic
bnormalities. t
4ollow-up Procedures
After discharge from the inpatient transplant unit,
atients were observed closely by the transplantation
eam until transfusion independence and resolution of
ctive issues. Subsequently, patients were asked to
eturn to the Johns Hopkins outpatient clinic period-
cally for a minimum of 5 years. Patients afterward
ither continued to return to Johns Hopkins for an-
ual evaluation or saw their referring oncologists for
ll care. Remission status and vital status were moni-
ored by the data management ofﬁce at least annually.
ethods of ascertaining remission and survival status
ncluded contacting family members or the referring
hysician’s ofﬁce, scanning obituaries, searching the
ocial Security Death Index, and obtaining death cer-
iﬁcates through vital records agencies.
Study variables included basic demographic data,
istology, type of CNS treatment, systemic remission
tatus at the time of BMT, presence of residual neu-
ologic signs or symptoms, preparative regimen, type
f graft, administration of intrathecal consolidation
herapy, and occurrence of neurologic complications
fter BMT. Neurotoxicities were graded according to
he National Cancer Institute common toxicity crite-
ia, version 2.0.
tatistical Analysis
A primary aim was to determine prognostic factors
or BMT recipients with a history of CNS involve-
ent by lymphoma. The primary statistical end points
ere relapse, diagnosis of a second malignancy, and
ll-cause mortality after BMT. Event-free survival and
verall survival rates were estimated by using the
roduct-limit method [15], with calculation of the
5% conﬁdence interval (CI). Event-free survival was
eﬁned as the interval between the date of BMT and
he date of relapse, diagnosis of a second malignancy,
eath from any cause, or the date last known to be
live and disease free. Overall survival was deﬁned as
he interval between the date of BMT and the date of
eath or last contact. Survival outcomes according to
rouped variables were compared by using the log-
ank statistic [16].
Several potential prognostic factors were analyzed to
etermine their effect on the recurrence of systemic or
NS disease and overall survival. Hazard ratios for
vent-free and overall survival were estimated by using
he proportional hazards model [17]. A hazard ratio 1
ndicated an increased risk of treatment failure associated
ith having the variable relative to its reference level. To
ccount for the simultaneous effects of more than 1
rognostic factor, a multivariate proportional hazards
odel was used. Candidate predictors were selected
rom the factors that seemed to be signiﬁcant or almost
igniﬁcant in univariate analysis. All such prognostic fac-
ors were included in the proportional hazards model.
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CNS Lymphoma and BMT
Bonsigniﬁcant variables were sequentially removed, and
azard ratios and signiﬁcance levels were re-estimated
fter each step. We also investigated possible differences
n the early event rates in the allogeneic and autologous
MT subsets. To do this, survival times were truncated
t 12 months, and patients who had events after this
utoff were censored at 12 months. Analyses were per-
ormed with SAS software for Windows, version 8.02
SAS Institute, Cary, NC). All P values reported are 2
ided.
ESULTS
atient Characteristics
From a group of more than 750 NHL patients
ndergoing BMT, 37 were identiﬁed who had prior
NS involvement and who were determined to be in
CNS remission by the time of BMT (Table 1). Four
dditional patients with CNS involvement were ex-
luded from analysis because there was persistent
NS disease at the time of BMT or because the CNS
emission status at the time of BMT was uncertain;
hese 4 patients died of either relapse or transplant-
elated complications. The median age at diagnosis
as 23 years, and 12 patients (32%) were18 years of
ge when diagnosed with systemic lymphoma. The
hief histologic subtypes were diffuse large B-cell lym-
homa (43%) and T-cell lymphoblastic lymphoma/
eukemia (41%). In more than half, the diagnosis of
NS lymphoma was ﬁrst made in the setting of re-
apsed disease. Before high-dose therapy, all patients
eceived intrathecal chemotherapy, and the majority
eceived localized, whole-brain, and/or spinal irradia-
ion. Pretransplantation lumbar puncture results were
vailable for rereview in all cases but 1. Rare patients
ad persistent CSF pleocytosis that was assumed to be
econdary to meningeal inﬂammation from the CNS
herapy.
Fifteen patients (41%) received allografts. Only 3
atients had systemic disease that was unresponsive to
he last regimen given before BMT; 2 of these received
llogeneic transplants. All patients received either cyclo-
hosphamide with TBI or the combination of busulfan
nd cyclophosphamide (Table 1). A minority received
dditional agents as part of these preparative regimens.
ore than half received consolidation with intrathecal
hemotherapy after BMT; most others were not able to
eceive it (eg, because of a transplant-related complica-
ion or early relapse).
elapse and Survival after BMT
As of last follow-up, 13 patients (35%) were alive
t a median of 10.2 years after transplantation (range,
.8 to 21.7 years). The median event-free survival of
he entire cohort was 5 months from the time of BMT
range, 0.2 months to 21.7 years), and the median u
B&MTverall survival was 10 months (range, 0.2 months to
1.7 years). The actuarial event-free survival was 40%
t 3 years (95% CI, 24%-56%) and 37% at 5 years
95% CI, 21%-53%; Figure 1). The actuarial overall
urvival was 39% at both 3 and 5 years (95% CI,
4%-55%; Figure 2).
Ten of 15 allogeneic transplant recipients and 14 of
2 autologous transplant recipients died. Fourteen pa-
ients (38%) died from relapsed lymphoma, and no pa-
ients were alive with relapsed disease as of last follow-
able 1. Patient Characteristics (n  37)
Variable Value
ge at diagnosis, y, median (range) 23 (2-65)
ge at diagnosis >18 y 25 (68%)
ge at BMT, y, median (range) 24 (2-71)
ale sex 28
tage
I 3
II 6
III 2
IV 26
istology
High grade 18 (49%)
T-cell lymphoblastic lymphoma/leukemia 15
Burkitt or Burkitt-like lymphoma/leukemia 3
Diffuse large B cell 16 (43%)
Anaplastic large cell 2
Chronic lymphocytic leukemia/small lymphocytic
lymphoma 1
NS lymphoma: presentation
Initial (before or during first-line chemotherapy) 15
Relapse (systemic or isolated CNS) 22 (59%)
ntraparenchymal CNS involvement 4
NS lymphoma: diagnosis
CSF: malignant cells  radiographic findings 32
CSF: suspicious cells  increased protein 1
CSF: suspicious cells  increased protein 
radiographic findings 1
CNS biopsy  malignant cells in CSF 3
NS lymphoma: treatment
Intrathecal therapy 9
Intrathecal therapy  radiation 25
Intrathecal therapy  radiation after resection 1
Intrathecal therapy  high-dose methotrexate 2
esidual neurologic signs or symptoms before BMT
Present 15
Unknown 1
ystemic disease status before BMT
Sensitive 33 (89%)
Resistant 3
Unmeasurable disease 1
reparative regimen
Cyclophosphamide, TBI 17
Doxorubicin, cyclophosphamide, TBI 2
Busulfan, cyclophosphamide 13
Busulfan, cyclophosphamide, etoposide 5
ype of BMT
Autologous 22 (59%)
Allogeneic 15
ntrathecal consolidation after BMT 22 (59%)
NS indicates central nervous system; CSF, cerebrospinal ﬂuid;
TBI, total body irradiation; BMT, blood or marrow transplan-
tation.p. It is interesting to note that all relapses occurred
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9ithin 13 months and that most (79%) occurred within
months of transplantation. In at least 5 patients there
as evidence of CNS relapse. In 1 patient who died of
isease progression, the site of relapse was unknown. In
nother patient, the disease status at the time of death
as unknown, but he was believed to be in remission
hortly beforehand. The causes of death in the allogeneic
ransplant recipients were relapse (n 4), sepsis (n 1),
espiratory failure (n 2), heart and renal failure (n 1),
epatic failure (n 1), and a second lymphoma that was
ransmitted from the donor, as previously described [18].
eaths in the autologous subgroup were due to relapse
n 10), aspergillosis (n 1), respiratory failure (n 1),
ardiac arrest from suspected cyclophosphamide-in-
uced cardiotoxicity (n  1), and complications from
eukoencephalopathy (n  1).
redictors of Survival
On univariate analysis (Table 2), the administra-
ion of consolidative intrathecal therapy after BMT
as associated with a 70% improvement in event-free
nd overall survival (P  .005 and P  .004, respec-
ively). Resistant systemic disease before BMT, resid-
al neurologic signs or symptoms before BMT, and
usulfan/cyclophosphamide conditioning were associ-
ted with a statistically signiﬁcantly inferior event-free
urvival and overall-survival: having resistant disease
as associated with a 7-fold increased risk of death
P  .004), having residual neurologic ﬁndings with a
2-fold increased risk (P  .04), and receiving busul-
an/cyclophosphamide with a 3-fold risk (P  .008)
ompared with receiving cyclophosphamide/TBI.
here was also a trend toward worse event-free and
verall survival as a function of older age: patients
lder than 18 years at the time of diagnosis were 2.5
imes as likely to die as younger patients (P  .07;
igure 3), and when age at BMT was grouped by
ecade, a cumulative 22% relative increase in risk of
igure 1. Kaplan-Meier estimates of event-free survival after BMT
n patients with prior central nervous system involvement by lym-
homa.eath per decade was observed (P  .06).
6There was no statistically signiﬁcant association
etween exposure to CNS irradiation and survival
fter BMT. There was also no signiﬁcant difference in
utcome according to the year in which BMT was
erformed. There were other factors that predicted
nferior outcomes, but the strength of the associations
id not reach statistical signiﬁcance. These included
istology other than Burkitt or T-cell lymphoblastic
ymphoma/leukemia, diagnosis of CNS disease in the
elapsed setting, intraparenchymal CNS involvement,
nd allogeneic BMT. The early (12-month) event
ates and death rates in the allogeneic and autologous
ubgroups are compared in Table 3.
Prognostic models were also explored through
ultivariate regression analysis. The ﬁnal results of
he step-down procedures are shown in Table 4. In
he ﬁrst and perhaps most robust multivariate
odel, resistant systemic disease and busulfan/cy-
lophosphamide conditioning were signiﬁcantly as-
ociated with an inferior outcome. A nearly signif-
cant (P  .06) inferior outcome was also associated
ith the presence of residual neurologic symptoms
t BMT. In contrast to the univariate analysis, the
ffect of intrathecal consolidation was not statisti-
ally signiﬁcant (ie, it was redundant with other
ffects retained in the model).
However, in a separate and nonoverlapping model
hat differed only by the exclusion of residual neuro-
ogic symptoms from the initial conditions, the previ-
usly described factors were no longer statistically
igniﬁcant (Table 4). Instead, the administration of
ntrathecal consolidation emerged as a strong inde-
endent prognostic factor for both event-free and
verall survival, with a 3-fold reduction in risk. Age
roup at diagnosis (adult versus pediatric) also
merged as an independent predictor of overall sur-
ival: older age adversely affected outcome. It is inter-
sting to note that the estimated 5-year overall sur-
ival was 58% (95% CI, 30%-86%) for pediatric
atients and 29% (95% CI, 10%-48%) for adult pa-
ients (P  .07; Figure 3).Figure 2. Kaplan-Meier estimates of overall survival after BMT.
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CNS Lymphoma and BMT
Beurologic Complications
Neurotoxicities, either transplant-related or possibly
ransplant-related, occurred in a number of cases and
ad variable clinical consequences. Although we do not
ave the results of formal neuropsychiatric testing for
ost patients, global functional status seemed to be pre-
erved on the last available assessment of the 13 surviving
atients.
Grade 1 toxicities manifested as possible mild cog-
itive decline were described in 4 patients. The ﬁrst
atient, who underwent BMT in early childhood and is
long-term survivor, had mild neurocognitive delay but
s functioning in school. The second patient, also pedi-
tric, has survived for 2 years and is likewise function-
ng in school with an average to low-average intelligence
uotient. The other patients, both adults, reported some
ifﬁculty with short-term memory or cognition; in 1 of
hese, a Mini-Mental State Examination was normal.
rade 2 toxicities included chemical arachnoiditis (n 
), transient visual changes (n 1), and sensory neurop-
thy in a patient who died of relapse. There was also a
ase of self-limited seizures that occurred more than 12
ears after BMT and was associated with a nontraumatic
unctate intracranial bleed without other neurologic se-
uelae.
Grade 3 toxicities consisted of chronic worsening
f preexisting neuropathic pain and weakness (n  1);
hronic lower extremity motor weakness (n  1);
hronic sensorineural hearing loss attributed to ami-
oglycosides (n  1); and leukoencephalopathy man-
fested as confusion, headache, and hearing loss, with
iffuse white matter changes, in a patient who died of
able 2. Univariate Predictors of Survival after BMT
Variable
Event-Free S
HR 95% CI
ge >18 y at diagnosis 2.27 0.84-6.17
lder age at BMT by decade 1.20 0.98-1.47
igh-grade histology* 0.61 0.26-1.44
NS disease at relapse† 1.71 0.73-4.02
ntraparenchymal disease‡ 1.89 0.56-6.44
NS irradiation before BMT 0.95 0.39-2.29
eurologic symptoms at BMT 2.32 1.01-5.33
ear of BMT§ 1.02 0.96-1.08
esistant systemic disease‡ 5.22 1.45-18.73
u-Cy-based regimen 3.17 1.33-7.51
llograft 1.21 0.54-2.75
VHD 0.93 0.39-2.25
ntrathecal consolidation 0.31 0.14-0.70
u indicates busulfan; CI, conﬁdence interval; CNS, central nervou
hazard ratio; BMT, blood or marrow transplantation.
Burkitt, Burkitt-like, or T-cell lymphoblastic lymphoma/leukemia
Compared with CNS disease diagnosed before or during ﬁrst-line
Based on 5 patients.
The reference year is 1980.
Compared with Cy/total body irradiation (TBI)-based regimens. Bu
was included in the Cy/TBI group.ther transplant-related complications (n  1). There a
B&MTas another case of leukoencephalopathy with pro-
ressive severe dementia that contributed to the pa-
ient’s death more than 10 years after BMT and was
herefore regarded as grade 5.
Additionally, there were 3 cases of life-threatening
erebral infarction or coma that occurred during the
arly posttransplantation period; all of these patients
ied. We view these cases as complications of BMT
ut not frank neurotoxicities, because they occurred in
he setting of severe infection, multisystem organ fail-
re, or both.
ISCUSSION
Many patients with a history of lymphomatous
nvolvement of the CNS have traditionally been ex-
igure 3. Kaplan-Meier estimates of overall survival after BMT
Overall Survival
P Value HR 95% CI P Value
.11 2.49 0.91-6.76 .07
.09 1.22 1.00-1.49 .06
.26 0.57 0.24-1.35 .20
.22 1.65 0.71-3.88 .25
.31 1.68 0.50-5.70 .40
.90 0.89 0.37-2.15 .79
.05 2.43 1.06-5.57 .04
.60 1.03 0.96-1.09 .43
.01 7.67 1.93-30.45 .004
.009 3.21 1.35-7.64 .008
.65 1.37 0.60-3.12 .45
.87 1.08 0.45-2.61 .87
.005 0.31 0.14-0.69 .004
m; Cy, cyclophosphamide; GVHD, graft versus host disease; HR,
ared with diffuse large B-cell lymphoma.
y.
oposide was included in the Bu/Cy group, and doxorubicin/Cy/TBIurvival
s syste
, comp
therap
/Cy/etccording to age at diagnosis of lymphoma (P  .07).
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9luded from high-dose systemic therapy, either be-
ause of concerns of increased toxicity or the percep-
ion of futility with this approach. Our long-term data
uggest that a history of lymphomatous involvement
f the CNS is not necessarily a poor prognostic fea-
ure in patients undergoing high-dose therapy and
MT. In this series, high-dose therapy produced du-
able remissions and long-term survival in a consider-
ble subset of patients with treated leptomeningeal or
ntraparenchymal lymphoma.
High-dose therapy in the setting of BMT affords
everal potential advantages in the treatment of CNS
ymphoma. The use of high-dose therapy may overcome
he inability of many chemotherapeutic agents to cross
he blood-brain barrier and the inconsistent distribution
f intrathecal or intraventricular chemotherapy. Busul-
an is one of the few agents that can cross the blood-
rain barrier and attain therapeutic concentrations in the
rain parenchyma [19,20]. Additionally, CNS involve-
ent with lymphoma is associated with a poor prognosis
n part because it often occurs in the setting of aggressive
isease or a high systemic tumor burden [14]. In a series
f patients with small non–cleaved-cell lymphoma
reated with standard-dose regimens, the event-free sur-
ival was similar in the presence or absence of CNS
isease after controlling for bone marrow involvement
r high serum lactate dehydrogenase levels [14]. Patients
ith a history of CNS involvement by lymphoma who
re treated with conventional therapy alone frequently
ie of systemic progression [21]. BMT has been shown
o be superior to conventional-dose therapy for patients
able 3. Early Failure Rates According to Type of Transplant
Variable
Type of
BMT
No.
Failures
E
vent Autologous 12
Allogeneic 9
eath Autologous 10
Allogeneic 9
I indicates conﬁdence interval; HR, hazard ratio; BMT, blood or
All follow-up times are censored as of 12 months after BMT.
able 4. Multivariate Regression Models for BMT Outcomes
Variable
Event-Free S
HR 95% CI
esistant systemic disease 5.09 1.20-21.65
u-Cy-based regimen 2.67 1.02-6.95
eurologic symptoms at BMT 2.40 0.96-6.02
esistant systemic disease 3.24 0.86-12.20
u-Cy–based regimen 3.21 1.25-8.26
ge >18 y at diagnosis 2.46 0.91-6.67
ntrathecal consolidation 0.29 0.13-0.66
u indicates busulfan; CI, conﬁdence interval; Cy, cyclophosphami
ach panel is a separate multivariate model.
8ith relapsed, chemosensitive, aggressive lymphomas
22]. High-dose therapeutic strategies aimed at more
ffectively eradicating systemic lymphoma in conjunc-
ion with CNS-directed therapy would conceivably yield
greater chance for prolonged survival than convention-
l-dose therapy alone [23].
Another important consideration is that patients
n this series did not have evidence of persistent CNS
ymphoma at the time of BMT. Patients with active
NS disease who receive high-dose therapy and BMT
ave distinctly poorer prognoses than those without
ctive CNS disease [12]. In a study of adult and pedi-
tric patients with NHL, the European Bone Marrow
ransplant Lymphoma Registry reported a progres-
ion-free survival of only 9% if the CNS disease was
ctive at the time of autologous BMT, compared with
2% if the CNS was cleared [12]. In fact, the out-
omes of patients achieving CNS remission before
MT were not signiﬁcantly different from those of
atched patients without a history of CNS involve-
ent [12].
In this review, we identiﬁed a number of poten-
ially independent prognostic factors for survival after
MT in patients with prior CNS involvement by
ymphoma. Age at diagnosis (adult versus pediatric),
isease chemosensitivity before BMT, the type of pre-
arative regimen, and the receipt of intrathecal con-
olidation were statistically signiﬁcantly associated
ith outcome in multivariate models. Whether intra-
hecal consolidation confers a true survival advantage,
r whether it is simply a marker for those who survive
e Failure Rate
(patient mos) HR 95% CI
0.078 1.00 —
0.096 1.24 0.81-1.89
0.057 1.00 —
0.087 1.52 0.97-2.38
w transplantation.
Overall Survival
P Value HR 95% CI P Value
.03 7.19 1.58-32.68 .01
.05 2.76 1.06-7.18 .04
.06 2.34 0.98-5.59 .06
.08 5.45 1.28-23.16 .02
.02 3.21 1.25-8.29 .02
.08 2.85 1.05-7.75 .04
.003 0.28 0.12-0.63 .002
, hazard ratio; BMT, blood or marrow transplantation.xposur
(mo)*
155
94
174
103
marrourvival
de; HR
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CNS Lymphoma and BMT
Bhe immediate posttransplantation period and are able
o receive consolidation, remains to be determined.
Neurologic complications after BMT may be in-
reased in those with a history of CNS disease and
ave been seen with variable frequency [11,13]. We
id not observe the relatively high rate of seizures
eported by one group [13], perhaps because of dif-
erences in patient characteristics, methods of CNS
reatment, or preparative regimens. Although there
ere a few cases of severe neurotoxicities, including 1
ase of progressive, fatal leukoencephalopathy, most
f the neurotoxicities were mild and did not seem to
ffect long-term outcome or functional status. Be-
ause of the relatively few severe neurotoxicities ob-
erved in this series, we could not assess the inﬂuence
f factors such as age, prior CNS irradiation, or pre-
arative regimen on the rate of development of these
omplications. Patients may have heightened suscep-
ibility to neurologic complications because of their
revious exposure to CNS irradiation or intrathecal
hemotherapy and possibly because of preexisting
eurologic signs and symptoms. Intrathecal chemo-
herapy and CNS irradiation may result in a spectrum
f neurotoxicities, including spinal cord damage and
ognitive decline. The choice of preparative regimen
ay also be important in this regard; systemic admin-
stration of high doses of cyclophosphamide in com-
ination with high doses of busulfan or TBI can in-
rease the risk of neurologic complications [24,25].
Given the limitations inherent to a retrospective
tudy and the generally low frequency of prior CNS
ymphoma in transplant recipients, several central
uestions remain. Because of the variability in patient
haracteristics and transplantation procedures, one
annot draw deﬁnite conclusions about the inﬂuence
f histologic subtype, type of CNS treatment, prepar-
tive regimen, type of graft, or intrathecal consolida-
ion on ultimate outcome. From this analysis, we are
lso unable to address what proportion of patients
ith a history of CNS lymphoma actually receive
MT. Nevertheless, our results are consistent with
hose of other groups, who have also found that a
ubset of patients with CNS involvement can achieve
ong-term survival with high-dose therapy and BMT
11,13]. For instance, in 20 adults with prior CNS
nvolvement by a variety of hematologic malignancies,
ncluding NHL, van Besien et al. [13] reported a
-year disease-free survival of 23%. In 15 adults with
HL undergoing autologous BMT, most of whom
id not have active CNS disease, Alvarnas et al. [11]
ound a 5-year actuarial event-free and overall survival
f 40%.
Long-term survival can be achieved through high-
ose therapy and BMT in patients with secondary
NS involvement by NHL who are treated in an
ggressive manner to induce a CNS remission. Thus,
f otherwise indicated, patients with prior, controlled 1
B&MTNS involvement by NHL should be offered BMT
ith curative intent. This approach can translate into
ong-term disease-free survival rates that are compa-
able to those of other high-risk patients who do not
ave CNS disease.
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